Hikma Pharmaceuticals PLC (HIK) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded.
Total Cash From Operating Activities Chart for Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC (HIK) operating cash flow for FY2025 was GBP 366.5M, a -35.0% change from FY2024. Hikma Pharmaceuticals PLC's operating cash flow grew from GBP 14.4M in 2002 to GBP 366.5M in 2025 (2453.7% over 23 years). Operating cash flow compound annual growth rate: 5-year CAGR of -4.6%, 10-year CAGR of 0.0%, 20-year CAGR of 12.8%.
Total Cash From Operating Activities (British Pounds)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- £3.40B
- Implied Share Price
- £16.41
- Enterprise Value
- £4.62B
- Revenue (TTM)
- £3.42B
- EBITDA
- £879.00M
- Profit Margin
- 11.32%
- Trailing P/E
- 12.72
- Forward P/E
- 9.70
- Price/Book (MRQ)
- 1.84
- Price/Sales (TTM)
- 0.99
- EV/EBITDA
- 7.29
- EV/Revenue
- 1.84
- Dividend Yield
- 5.24%
- Book Value
- £8.54
- Free Cash Flow (FY2025)
- £165.40M
- Free Cash Flow Yield
- 4.87%
Snapshot as of 27th August 2026 — not point-in-time controlled, may lag the live market by a few days.